WO2011049539A1 - Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil - Google Patents

Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil Download PDF

Info

Publication number
WO2011049539A1
WO2011049539A1 PCT/TR2010/000208 TR2010000208W WO2011049539A1 WO 2011049539 A1 WO2011049539 A1 WO 2011049539A1 TR 2010000208 W TR2010000208 W TR 2010000208W WO 2011049539 A1 WO2011049539 A1 WO 2011049539A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
dry powder
corticosteroid
nedocromil
cromoglicic acid
Prior art date
Application number
PCT/TR2010/000208
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011049539A1 publication Critical patent/WO2011049539A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to pharmaceutical compositions in dry powder form comprising a pharmaceutically effective amount of cromoglicic acid and/or nedocromil salts in addition to p 2 -agonists and corticosteroid drugs for the use in the treatment of the respiratory diseases.
  • the drugs included in this group are categorized into two main groups as mentioned before.
  • the first of them is p 2 -agonists comprising salbutamol, levosalbutamol, prosaterol, fenoterol, terbutaline, pirbuterol, metoproterenol, bitolterol mesilate which affects rapidly but lose its effect in a short time.
  • the second group consists of salmeterol, formoterol, bambuterol and clenbuterol and they affect slowly compared to the other group and are characterized by their long-lasting effects.
  • the drugs named as Albuterol (Ventolin, Proventil), metaproterenol (Alupent), pirbuterol (Maxair), terbutaline (Brethaire), isoetharine (Bronkosol), and Levalbuterol (Xopenex), salmeterol xinafoate (Serevent) in the markets can be examples of the pharmaceutical compositions comprising the molecules included in this group.
  • corticosteroids Another drug group that is often used for the treatment of asthma and COPD is corticosteroids.
  • the molecules included in this group are used since approximately 1950s. These molecules lead to opening of the air vessels by controlling inflammation and hence decreasing mucus that forms the basis of asthma and makes the problems of asthma patients disappear for this reason.
  • the drugs included in this group are taken systemically, they cause serious side effects such as osteoporosis, high cholesterol, oedema, headache, sleep problems, some skin problems and growth retardation in children. Therefore, transmission methods in which lowest possible amount of these drugs enters to systemic circulation should be preferred.
  • transmission of these kinds of molecules is applied by inhalation route in order to decrease the side-effect and to transport the highest possible maximum dose to the pulmonary system.
  • ⁇ -agonist drugs trigger respiratory diseases, for preventing the side effects of these substances which are essential for use in the treatment of asthma, the combination of them with the other substances effective on the same disease is beneficial for both decreasing the amount of p 2 -agonists to be taken and for the benefits of the synergic effects for the patients arising from the combination of two different drugs. For that reason, it is found that using p 2 -agonists and corticosteroids together provides; decrease in the amount of p 2 -agonists used, opening bronchus with the positive effect of this drug, and preventing the inflammation resulting from asthma by usingcorticosteroid.
  • nebulization devices which are suitable for use in the transmission of drug by inhalation route. These are; (a) nebulization devices, (b) inhalators including pressurized gas and (c) dry powder inhalators.
  • the nebulization devices are often not preferred due to their large sizes and due to the fact that they sometimes cause infection.
  • the inhalators including pressurized gas which is the other method are more advantageous than nebulizers since they can be easily carried, but in these devices the largest part of the dose accumulates in different points of the respiratory tract and enters the systemic circulation before it reaches the lungs and under the best circumstances only 10-20% of the drug taken reaches to the target area, in other words, in the case where the drug is taken by the patient with 100% efficiency.
  • Anjmportant factor causing this situation is that the carrier gas used in these devices cause cold freon effect and as a consequence of this phenomenon the respiration of the patient stops for a short period while using the drug and the drug accumulates in the mouth instead of reaching to the target area by breathing of the drug.
  • the inhalators including pressurized gas in transmission of these group of drugs is not a correct choice for the patients.
  • the inhalators including dry powder come into prominence due to their ease of use. These devices can be moved to everywhere due to the fact that they have small size and they do not cause the cold freon effect since they do not comprise a carrier gas. Moreover, contrary to the inhalators including pressurized gas, simultaneous pressing and breathing are not required and this plays an important role on effective inhalation of the drug by the patients.
  • inhalators comprising dry powder in three groups, one of them is the inhalators comprising disposable capsule. These are not mostly preferred because of the fact that a new capsule should be placed before each use.
  • Another inhalator including dry powder is the inhalators having reservoir comprising the dry powder. These are beneficial since they provide multiple dosing but these devices are not sufficient for providing the dose uniformity.
  • Another type of dry powder inhalator is the devices in which the drug is placed in the blister.
  • the devices including blister; (a) are more advantageous than the devices comprising reservoir since it provides intake of the right dose amounts via filling each dose into different blister cavities in the factory.
  • Lactose which is a disaccharide
  • the amount of lactose used is usually in the range of 10 mg to 25 mg in a single dose and this is approximately 500-2500 times the amount of active agent used.
  • lactose used as a carrier in dry powder formulation when used in large amounts cause side effects such as coughing, throat irritation, etc.
  • dry powder formulations containing large amount of lactose when used by patient with allergy and/or lactose intolerance causes symptoms such as nausea, stomach cramps, overfullness of the stomach, swelling of stomach, flatus, diarrhea, hives plaque. Only some part of the drugs administered by inhalation can reach the target area, the rest is mostly swallowed. Therefore, it is required to develop the compositions comprising p 2 -agonists and corticosteroid within the scope of the present invention.
  • Salts of cromoglicic acid and nedocromil are used for the treatment of bronchospasm in pharmacology. Because of this property of it, it is used for the treatment of asthma, allergic rhinitis, allergic and vernal conjunctivitis diseases.
  • Products comprising acid derivatives and providing up to 20 mg sodium cromoglicate per dose, are marketed by the trademarks of "Intal” and “Cromohexal”.
  • cromoglicic acid derivatives are used as a solubility enhancing agent in some aerosol formulations.
  • US6475467 relates to use of a compound selected from cromoglicic acid and nedocromil derivatives in an ineffective amount in aerosol formulation that is in the form of suspension for increasing the dispersion of active agent in this suspension.
  • cromoglicic acid and nedocromil derivatives optionally alone or combined with lactose as a carrier increases the remedial effect of the pharmaceutical compositions and also decreases the side effects arising from use of lactose in high amounts.
  • the present invention is related to the use of cromoglicic acid and/or nedocromil salts in the dry powder formulations comprising 2 -agonists and corticosteroids or their pharmaceutically acceptable derivatives. Initially, in the dry powder formulations comprising 2 -agonists and corticosteroids, cromoglicic acid and/or nedocromil salts are added to the formulation for decreasing lactose amount and hence the side effects resulting from lactose.
  • cromoglicic acid and/or nedocromil salts are used in effective amounts, it has been found that a synergistic effect between these effective substances and an unexpected benefit in the treatment of the respiratory diseases takes place. Therefore, in the present invention, cromoglicic acid and/or nedocromil salts are used in the inhalation formulations in dry powder form comprising the combination of p 2 -agonist and corticosteroid, this way the carrier amount has decreased and thus the side effects arising from the carrier has been minimized and also an unexpected therapeutical benefit in the treatment of respiratory diseases has been observed.
  • the present invention is related to the pharmaceutical composition for use for the treatment of respiratory diseases in which the combination of p 2 -agonist and corticosteroid and cromoglicic acid and/or nedocromil salts are combined together in effective doses.
  • the inventors have faced with the usually experienced problem of not being able to provide the effective amount of dose in the inhalation formulations in dry powder form comprising the combination of p 2 -agonist and corticosteroid and cromoglicic acid and/or nedocromil salts. In order to solve this problem, several methods and devices were tried.
  • blister strip package which is reliable in terms of hygiene and also which discards the possibility of moistening of the dry powder and additionally helps the dosage to be adjusted has been preferred.
  • an aspect of the present invention comprises that the dry powder composition comprising 2 -agonist and corticosteroid and cromoglicic acid and/or nedocromil salts is stored in the blister strip package opened by peeling off and is applied to the patient by the dry powder inhaler device.
  • the blister strip package which is preferred to be used in the present invention opened by peeling consists of two layers. At the bottom layer, the blister cavities comprising the dry powder formulations are present. The top layer acts as a lid and peeling said top layer results in opening blisters in order to make the dry powder formulation ready for inhalation.
  • the present invention provides a method comprising delivery of the pharmaceutical composition comprising effective amounts of the combination of p 2 -agonist and corticosteroid and cromoglicic acid and/or nedocromil salts and optionally a pharmaceutically acceptable carrier stored in blister strip package by a dry powder inhalation device for the treatment of the patients having respiratory diseases, especially for the patients having allergic diseases.
  • p 2 -agonists that can be used in said invention can be chosen from but not limited by a group comprising salbutamol, levosalbutamol, prosaterol, fenoterol, terbutaline, pirbuterol, metoproterenol, bitolterol mesilate, salmeterol, formoterol, bambuterol and clenbuterol and their pharmaceutically acceptable salts, esters, solvates thereof.
  • Corticosteroid that can be used in said invention can be chosen from but not limited by triamcinolone, beclomethazone, mometasone, ciclesonid, budesonide and flutikasone or their pharmaceutically acceptable salts, solvates, derivatives thereof.
  • Cromoglicic acid and/or nedocromil salts that can be used in said invention can be chosen from its pharmaceutically acceptable salts. It can be preferably selected from sodium chromoglycate and/or nedocromile sodium.
  • the dry powder composition that can be inhaled by inhalation route can optionally comprise another carrier.
  • These carriers can be chosen from sugar alcohols such as arabinose, glycose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol or from saccharides .
  • the pharmaceutical composition in accordance with the present invention is in the form of micronized dry powder particles.
  • the active agents present in said composition have average particle size of 1 to 20 ⁇ , preferably 1 to 5 ⁇ .
  • the carrier present in said composition typically has average particle size of not more than 300 ⁇ , preferably not more than 210 ⁇ .
  • Salt of cromoglicic acid and/or nedocromil present in said composition both as an active agent and as an excipient, has average particle size in the range of 1 to 20 ⁇ and in the range of 10 to 300 ⁇ .
  • the cavity volume of each blister in blister strip package contained in the dry powder inhaler which is used for delivery of said composition to the lungs is in the range of 20 to 30 mm 3 , preferably in the range of 21 to 25 mm 3 , most preferably in the range of 22 to 23 mm 3 .
  • Lid sheet and base sheet of said blister strip are closed very tightly by a suitable method to provide impermeability.
  • the lid and base sheet comprising the blister strip package in accordance with the present invention consists of three- layers. Two of these layers are polymeric layers and the other one is aluminium foil. Aluminium foil is used in both lid sheet and base sheet of the blister strip to provide high humidity and gas protection due to the fact that aluminium foil is conventionally used in both lid sheet and base sheet of blister strip package for high humidity and gas protection. These layers must have the sufficient thickness which provides the protection for the stability of hygroscopic dry powder formulation which is stored in blister cavity. Because of this reason, the thickness of aluminium foil that is used in lid sheet and base sheet of the blister strip package is in the range of 10 to 40 ⁇ , preferably in the range of 15 to 40 ⁇ .
  • lid sheet and base sheet of the blister strip Two of the layers contained by lid sheet and base sheet of the blister strip according to the present invention are polymeric layers. These polymeric layers may be made from either same or different polymers. The thickness of these polymeric layers depends on the type of polymeric substance used and its properties. Therefore, the thickness of each polymeric layer which is used in lid sheet and base sheet of said blister strip is in the range of 15 to 60 ⁇ , preferably of 20 to 35 ⁇ depending on the type of used polymer.
  • the polymers used for forming polymeric layers are preferably selected from a group comprising thermo-plastic polymers such as polyethylene, polypropylene, polystyrene, polyolefm, polyamide, polyvinyl chloride, polyurethane.
  • the layers making up lid sheet and base sheet of said blister strip in accordance with present invention are preferably same for each sheet, however the polymeric substances used for forming polymeric layers are preferably different from each other. Moreover, each of the blister cavities which constitute the blister strip, can be different in shape as long as it has the properties defined above.
  • Devices used to inhale the dry powder formulation in accordance with the present invention may be multi dose inhalers present in the prior art. For this reason, the invention provides a pharmaceutical composition as it is mentioned before. In another aspect, the invention provides a method for delivery of pharmaceutical composition to patient's lungs effectively as mentioned before.
  • the pharmaceutical composition containing active agents which is in dry powder form is stored in a blister strip and during dosing with a multi dose inhalator, with each movement of the device it can deliver 5 to 50 milligram of the dry powder wherein one each dose comprises the combination of p 2 -agonist and corticosteroid and cromoglicic acid and/or nedocromil salts .
  • the combination of p 2 -agonist and corticosteroid can be present in the amount of 1 to 1000 ⁇ g
  • cromoglicic acid and/or nedocromil salt can be present in the amount of 5 to 50 mg.
  • the ratio of the total weight of the combination of p 2 -agonist and corticosteroid to the weight of cromoglicic acid and/or nedocromil salt in said pharmaceutical composition is in the range of 1 :5 to 1 : 10000.
  • any pharmaceutically acceptable carrier can be used for the purpose of adjusting each dose of pharmaceutical composition which is in dry powder form to the range of 5 mg to 50 mg.
  • composition in accordance with the present invention can be used for the treatment of many respiratory diseases such as asthma, chronic obstructive pulmonary disorder (COPD) and allergic rhinitis.
  • the respiratory diseases include but are not restricted to; allergic or non-allergic asthma in various phases, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airways hyperactivity, bronchiectasis, chronic obstructive pulmonary, airways or lung diseases (COPD, COAD or COLD) including emphysema and chronic bronchitis, pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
  • the treatment of said diseases may be prophylactic or symptomatic.
  • the pharmaceutical composition in accordance with the present invention is used especially for the symptomatic treatment of asthma, allergic rhinitis and CO

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique utilisée pour traiter des maladies respiratoires, laquelle composition est caractérisée en ce qu'elle comprend, outre des β2-agonistes et des médicaments à base de corticostéroïdes, une quantité pharmaceutiquement efficace d'acide cromoglicique et/ou de sels de nédocromil.
PCT/TR2010/000208 2009-10-20 2010-10-20 Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil WO2011049539A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2009/07914 2009-10-20
TR2009/07914A TR200907914A2 (tr) 2009-10-20 2009-10-20 Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.

Publications (1)

Publication Number Publication Date
WO2011049539A1 true WO2011049539A1 (fr) 2011-04-28

Family

ID=43734282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000208 WO2011049539A1 (fr) 2009-10-20 2010-10-20 Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil

Country Status (2)

Country Link
TR (1) TR200907914A2 (fr)
WO (1) WO2011049539A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015086276A1 (fr) * 2013-12-09 2015-06-18 Pharmachemie B.V. Inhalateur de poudre sèche
CN109715153A (zh) * 2016-07-07 2019-05-03 迪亚特实验室诊断和治疗应用公司 用于治疗皮炎的包含色甘酸的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398631A1 (fr) * 1989-05-17 1990-11-22 FISONS plc Composition pharmaceutique
WO1993011744A1 (fr) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
WO2000007567A1 (fr) * 1998-08-04 2000-02-17 Jago Research Ag Formulations d'aerosol a usage medical

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398631A1 (fr) * 1989-05-17 1990-11-22 FISONS plc Composition pharmaceutique
WO1993011744A1 (fr) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
WO2000007567A1 (fr) * 1998-08-04 2000-02-17 Jago Research Ag Formulations d'aerosol a usage medical
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015086276A1 (fr) * 2013-12-09 2015-06-18 Pharmachemie B.V. Inhalateur de poudre sèche
EP3398638A1 (fr) * 2013-12-09 2018-11-07 Pharmachemie B.V. Inhalateur de poudre sèche
EA034245B1 (ru) * 2013-12-09 2020-01-21 Фармахеми Б.В. Фармацевтическая композиция для вдыхания для лечения респираторного заболевания, её применение и способ лечения респираторного заболевания
US11020546B2 (en) 2013-12-09 2021-06-01 Pharmachemie B.V. Dry powder inhaler
US11642475B2 (en) 2013-12-09 2023-05-09 Pharmachemie B.V. Dry powder inhaler
CN109715153A (zh) * 2016-07-07 2019-05-03 迪亚特实验室诊断和治疗应用公司 用于治疗皮炎的包含色甘酸的组合物

Also Published As

Publication number Publication date
TR200907914A2 (tr) 2011-05-23

Similar Documents

Publication Publication Date Title
EP2528585B1 (fr) Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide
EP2528596B1 (fr) Composition sous forme de poudre sèche pour administration par inhalation comprenant une combinaison de bromure de tiotropium, de xynafoate de salmeterol et de propionate de fluticasone.
RU2019100425A (ru) Новая доза и препаративная форма
ES2613754T3 (es) Uso de glicopirrolato para tratar la taquicardia
EA023839B1 (ru) Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
WO2011093819A2 (fr) Nouvelle composition pharmaceutique combinée comprenant du tiotropium
WO2011093820A2 (fr) Composition pharmaceutique combinée comprenant du tiotropium
EP2533765A2 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
WO2011093818A2 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
WO2011136753A1 (fr) Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
WO2011049539A1 (fr) Compositions comprenant un corticostéroïde, un agoniste bêta2 et de l'acide cromoglicique ou du nédocromil
EP2490681B1 (fr) Composition pharmaceutique sous forme de poudre seche
EP2528597B1 (fr) Composition sous form de poudre sèche comprenant une combinaison de bromure de tiotropium, fumarate de formoterol et de furoate de mometasone
WO2011093811A2 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
EP2515848B1 (fr) Combinaison de poudre sèche constituée de tiotropium, d'un corticostéroïde et d'un dérivé d'acide cromoglicique
WO2011093814A2 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
EP2515845A1 (fr) Combinaison de poudres sèches de tiotropium, de formotérol et d'un dérivé d'acide cromoglycique
WO2011093812A2 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
CA2528863A1 (fr) Doses combinees
US20130022650A1 (en) Compositions containing salmeterol, fluticasone and cromoglicic acid
WO2011049538A2 (fr) Composition pharmaceutique sous forme de poudre sèche
EP2815739B1 (fr) Procédé de remplissage de composition d'inhalation
EP2515846B1 (fr) Combinaison de tiotropium, budesonide et acide cromoglicique en composition de poudre sèche
WO2011136752A1 (fr) Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
WO2011093810A2 (fr) Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10795798

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 10795798

Country of ref document: EP

Kind code of ref document: A1